Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

Respiratory Syncytial Virus (RSV) News Releases

Investigational Vaccine Protects Cattle from Respiratory Syncytial Virus
March 10, 2017

A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according to research published online in npj Vaccines on March 8. The research was conducted by a team of experts at NIAID, the Pirbright Institute based in the United Kingdom, and the Institute for Research in Biomedicine in Switzerland.

Respiratory Syncytial Virus Vaccine Enters Clinical Testing
February 22, 2017

A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial also will assess the vaccine’s ability to prompt an immune response in healthy adult participants. The investigational vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.

RSV Pediatric Vaccine Candidate Shows Promise in Early Clinical Trial
November 5, 2015

Scientists from the National Institute of Allergy and Infectious Diseases and colleagues  have developed a vaccine candidate to protect infants and young children against respiratory syncytial virus that appears to elicit a stronger protective immune response than the previous lead vaccine candidate.

NIH Launches Human RSV Study
August 26, 2015

​A new study will expose healthy adult volunteers to respiratory syncytial virus (RSV). Better understanding of how adults develop RSV infection and immune system responses to infection will help researchersdevelop and test future antivirals and vaccines to combat the virus. 

NIH Scientists Develop Candidate Vaccine Against Respiratory Syncytial Virus
October 31, 2013

An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science. Early-stage human clinical trials of the candidate vaccine are planned.

NIH Study Offers Clues to Making Vaccine for Infant Respiratory Illness
April 25, 2013

An atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody represents a leap toward developing a vaccine for a common-and sometimes very serious-childhood disease. The findings, by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, define the vulnerable shape of a critical RSV component called the fusion glycoprotein.